COMMUNIQUÉS West-GlobeNewswire

Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
14/05/2025
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal vaccine and [...]
Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre
14/05/2025
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre La Société est en bonne voie pour obtenir l'autorisation de mise sur le marché au deuxième trimestre 2025 Les [...]
Nyxoah Reports First Quarter Financial and Operating Results
14/05/2025
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final [...]
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
14/05/2025
PRESS RELEASE Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting Milan, ITALY – 14 May 2025 – Genespire, a [...]
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome
14/05/2025
Communiqué de presse Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans le glaucome Plusieurs paramètres de l’humeur aqueuse stimulés par l’oxyde nitrique ont été statistiquement significatifs [...]
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
14/05/2025
Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
14/05/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
14/05/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE [...]
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
14/05/2025
MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen [...]
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed [...]
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
13/05/2025
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of [...]
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
13/05/2025
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June Regenerative Medicine [...]
Glass House Brands Reports First Quarter 2025 Financial Results
13/05/2025
Wholesale biomass production was 152,568 pounds, up 149% year-over-year Cost of production was $108 per pound, a substantial improvement compared to $182 per pound in Q1 2024 First quarter 2025 revenue was $44.8 million [...]
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/05/2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]
NeuroPace Reports First Quarter 2025 Financial Results
13/05/2025
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to [...]
Iridex Reports First Quarter 2025 Financial Results
13/05/2025
MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Spectral AI Announces 2025 First Quarter Financial Results
13/05/2025
Q1 Overview Research & Development Revenue of $6.7 Million Improved Capital Structure Reflected in Cash of $14.1 Million Continued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May [...]
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
13/05/2025
Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated [...]
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
13/05/2025
Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company ’ s commercial launches and [...]

Pages